Aeolus Pharmaceuticals Inc. (OTCPK:AOLS) announced a private placement of 6% convertible promissory notes for gross proceeds of $1,000,000 with existing investor Biotechnology Value Fund L.P., a fund managed by BVF Partners LP on September 29, 2015. The note carries a fixed interest rate of 6% per annum and would mature September 28, 2016. The outstanding principal and accrued interest on the notes shall automatically convert into company equity securities issued in a qualified transaction at a conversion rate carrying a 15% discount to the lowest price per share issued in a qualified transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 152 | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AOLS Stock
- News Aeolus Pharmaceuticals, Inc.
- Aeolus Pharmaceuticals Inc. announced that it has received $1 million in funding from BVF Partners LP.